A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT ID: NCT07269210
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
60 participants
INTERVENTIONAL
2025-12-08
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY3475766 in Healthy Participants
NCT04052594
A Study of LY3502970 in Healthy Overweight and Obese Participants
NCT05313802
A Study of LY3561774 in Participants With Mixed Dyslipidemia
NCT05256654
A Study of LY3561774 in Participants With Dyslipidemia
NCT04644809
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Solbinsiran
Participants will receive solbinsiran subcutaneously (SC)
Solbinsiran
Administered SC
Placebo
Participants will receive placebo SC
Placebo
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Solbinsiran
Administered SC
Placebo
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fasting triglyceride level ≥500 mg/dL at two separate visits during screening (at least 7 days apart)
* Have a body mass index (BMI) within the range of 18.5 to 45.0 kilograms per square meter (kg/m2) (inclusive)
Exclusion Criteria
* Have a history of acute pancreatitis within 12 months prior to screening
* Have a known genetically confirmed diagnosis of Familial Chylomicronemia Syndrome
* Have a history of or planned treatment involving any gene editing or gene therapy modalities, including but not limited to CRISPR-based, viral vector-mediated, or other genetic modification techniques
* Have a history of chronic alcohol abuse within 3 years prior to screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Axsendo Clinical Research - Peak Heart & Vascular - Phoenix
Phoenix, Arizona, United States
Synexus Clinical Research US, Inc./Orange Grove Family Practice
Tucson, Arizona, United States
National Heart Institute
Beverly Hills, California, United States
Ark Clinical Research
Long Beach, California, United States
Catalina Research Institute, LLC
Montclair, California, United States
Valley Clinical Trials, Inc.
Northridge, California, United States
CMR of Greater New Haven, LLC
Hamden, Connecticut, United States
Northeast Research Institute - Downtown Office
Jacksonville, Florida, United States
Novera Clinical Research
Miami, Florida, United States
Inpatient Research Clinic
Miami Lakes, Florida, United States
Clinical Site Partners, LLC dba Flourish Research
Winter Park, Florida, United States
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, United States
Investigators Research Group
Brownsburg, Indiana, United States
Saint Elizabeth Healthcare - Saint Elizabeth Covington Hospital
Covington, Kentucky, United States
Flourish Research - Bowie
Bowie, Maryland, United States
University of Massachusetts Chan Medical School
Worcester, Massachusetts, United States
AB Clinical Trials
Las Vegas, Nevada, United States
Clinical Research of Philadelphia
Pennington, New Jersey, United States
Weill Cornell Medical College
New York, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Cardiovascular Specialists of Willowbrook
Houston, Texas, United States
Southern Endocrinology Associates
Mesquite, Texas, United States
American Research Corporation at Texas Liver Institute
San Antonio, Texas, United States
Endeavor Clinical Trials
San Antonio, Texas, United States
Stroobants Cardiovascular Center
Lynchburg, Virginia, United States
TPMG (Tidewater Physicians Multispecialty Group) Clinical Research
Newport News, Virginia, United States
Carilion Clinic
Roanoke, Virginia, United States
Eastside Research Associates
Redmond, Washington, United States
UW Medicine Diabetes Institute
Seattle, Washington, United States
Ecogene-21
Chicoutimi, , Canada
C.I.C. Mauricie inc.
Trois-Rivières, , Canada
ARC Biosystems
Vancouver, , Canada
Peking University Third Hospital
Beijing, , China
Sichuan Provincial People's Hospital
Chengdu, , China
Guangdong Provincial People's Hospital
Guangzhou, , China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, , China
Zhongshan Hospital,Fudan University
Shanghai, , China
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, , China
The Institute of Medical Science, Asahi Life Foundation
Chūōku, , Japan
Takai Internal Medicine Clinic
Kamakura-shi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia (SOLARIS-1)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J3F-MC-EZCC
Identifier Type: OTHER
Identifier Source: secondary_id
27775
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.